Here are five insights:
1. Ionis is currently focused on a new undisclosed neurological disease target.
2. The FDA recently approved Ionis’ SPINRAZA, which is intended to treat pediatric and adult patients with spinal muscular atrophy.
3. Under the collaboration, Ionis has been able to commercialize SPINRAZA as well as develop four other drugs.
4. Ionis has also validated four other targets with potential drugs.
5. Ionis focuses on drug discovery and antisense therapies while Biogen works to develop therapies for neurological disorders.
More articles on devices:
Following successful study, Intralink-Spine promotes Rejuve as low back pain cure — 5 things to know
Exactech sells spine assets to ChoiceSpine: 5 things to know
SeaSpine unveils Vu a∙POD Prime NanoMetalene System for full commercial launch — 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
